Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients .

Sponsor
Beijing Tsinghua Chang Gung Hospital
Study ID
NCT06632522
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • radiotherapy combined with Camrelizumab and Apatinib — DRUG
    Camrelizumab is administered intravenously (without preventive medication), with a fixed dose of 200mg, with an infusion of 30 min (not less than 20 min and not more than 60 min) every three weeks. Apatinib, 250 mg, taken orally within half an hour after meals, QD, continuously.

Study Details

Clinical study of radiotherapy combined with Camrelizumab and Apatinib in the treatment of liver cancer patients with VP4.

Key Dates

Start date
Oct 20, 2024
Status verified
Oct 2024
Primary completion
Nov 30, 2025
Completion
Dec 30, 2026

Study Design

Enrollment
46 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: radiotherapy combined with Camrelizumab and Apatinib
    radiotherapy combined with Camrelizumab and Apatinib in the treatment of liver cancer patients with VP4

Primary Outcome Measure

Overall survival [ Time Frame: up to 3 years ]

Central Contacts

Related Studies